Furthermore, tumor-derived Fibrinogen-like protein 2 (FGL2) suppresses the differentiation of CD103+ dendritic cells, thereby impairing CD8+ T cell-mediated immune responses against glioblastoma [51]. This evidence concerns the gene CD8A and glioblastoma.